vaccines - versus control - for COVID-19 prophylaxis (children) pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

confirmed Covid-19, from 1st dose 0.09 [0.08, 0.10]< 10%2 studies (1/1)100.0 %NAnot evaluable crucial-
confirmed COVID (any severity) 0.10 [0.08, 0.13]< 164%10 studies (4/6)100.0 %NAlow important-
hospitalization 0.11 [0.06, 0.23]< 170%5 studies (-/5)100.0 %NAnot evaluable important-
symptomatic Covid-19 0.13 [0.03, 0.55]< 193%4 studies (2/2)99.7 %NAnot evaluable important-
asymptomatic COVID case 0.38 [0.20, 0.69]< 10%1 study (1/-)99.9 %NAnot evaluable non important-
ICU admission 0.02 [0.01, 0.05]< 10%1 study (-/1)100.0 %NAnot evaluable non important-
infection (PCR positive symptomatic or not) 99.10 [98.60, 99.60]< 10%1 study (-/1)0.0 %NAnot evaluable non important-
severe COVID-19 occurrence 0.04 [0.02, 0.09]< 10%1 study (-/1)100.0 %NAnot evaluable non important-
vaccine efficacy after dose 1 (and before dose 2) 5.01 [0.02, 1627.08]< 198%2 studies (1/1)30.0 %lownot evaluable highnon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.